Xinxiaoya

GenAssist Ltd Released Two Posters at the American Society of Gene & Cell Therapy (ASGCT) Breakthroughs in Muscular Dystrophy

GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company for genome medicines, announce that two of our posters for presentation will be released at American Society of Gene and Cell Therapy’s (ASGCT) Breakthroughs in Muscular Dystrophy, which will take place November 19-20, 2024, at The Westin Michigan Avenue Chicago, IL. Several latest advancements in first DMD […]

GenAssist Ltd Released Two Posters at the American Society of Gene & Cell Therapy (ASGCT) Breakthroughs in Muscular Dystrophy Read More »

GenAssist Ltd Released Six Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress

GenAssist Ltd (GenAssist), a pioneering gene-editing biotechnology company for genome medicines, released six posters for presentation at the ESGCT 31st Annual Congress, which is held from October 22-25, 2024, in Rome, Italy. Several latest advancements in base editing, DMD, and AAV vector design were featured by poster presentations from GenAssist at ESGCT, which covered a

GenAssist Ltd Released Six Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress Read More »

The First DMD Clinical Base Editing Drug! DMD Treatment is Entering the Gene Editing Era!

On September 06, 2024, GenAssist Ltd (GenAssist), announced that the first DMD patient has been successfully dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). “To date, no gene editing drug has entered clinical trials for DMD indication. This first-in-human dosing marks that DMD treatment has entered the gene editing era”,

The First DMD Clinical Base Editing Drug! DMD Treatment is Entering the Gene Editing Era! Read More »

GenAssisst Ltd announced the Pre-IND meeting request submitted to NMPA for GEN6050X injection, its first base editing drug against to Duchenne Muscular Dystrophy (DMD)

On July 29, 2024, Suzhou GenAssist Therapeutical Co., Ltd, the operation entity of GenAssist Ltd (GenAssist), announced that Pre-IND (PIND) meeting request for its first base editing DMD drug, GEN6050X, has be submitted to NMPA. Previously, the PIND meeting to FDA was held in April 2023. The PIND filing to FDA and NMPA indicated the

GenAssisst Ltd announced the Pre-IND meeting request submitted to NMPA for GEN6050X injection, its first base editing drug against to Duchenne Muscular Dystrophy (DMD) Read More »

GenAssisst Ltd announced the successful kickoff meeting of Investigator-Initiated Trial (IIT) for GEN6050X injection, its first base editing drug against Duchenne Muscular Dystrophy (DMD)

On May 30, 2024, Suzhou GenAssist Therapeutical Co., Ltd, the operation entity of GenAssist Ltd (GenAssist), announced that the IIT(NCT06392724) kickoff meeting for its first base editing DMD drug, GEN6050X, has be successfully held in Peking Union Medical College Hospital (PUMCH). This program is sponsored by Suzhou GenAssist Therapeutics and led by Professor Yi Dai,

GenAssisst Ltd announced the successful kickoff meeting of Investigator-Initiated Trial (IIT) for GEN6050X injection, its first base editing drug against Duchenne Muscular Dystrophy (DMD) Read More »

GenAssist expressed great gratitude to the valuable advice from the virtual TREAT-NMD Advisory Committee for Therapeutics (TACT) held in September 2023

GenAssist Therapeutics successfully completed a virtual meeting with the TREAT-NMD Advisory Committee for its first base editing product on September 29, 2023. Eighteen representatives, including distinguished preclinical and clinical experts in Duchenne Muscular Dystrophy (DMD) therapy, as well as DMD representatives attended this meeting. A comprehensive review and advice were received on November 13 after

GenAssist expressed great gratitude to the valuable advice from the virtual TREAT-NMD Advisory Committee for Therapeutics (TACT) held in September 2023 Read More »

TAM Base Editor can efficiently induce exon skipping in 42% of all DMD mutation types, reported by Professor Xing Chang at Cell Reports

Recently, the team led by Professor Xing Chang, West Lake University, published an article titled “Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers” in Cell Reports. In this paper, Han Q. et al employed Targeted AID-mediated mutagenesis (TAM) cytosine base editor (CBE-TAM) to edit various hotspot mutations of DMD gene in vitro. High

TAM Base Editor can efficiently induce exon skipping in 42% of all DMD mutation types, reported by Professor Xing Chang at Cell Reports Read More »

GenAssist, a Pioneer in the field of the Gene Editing Innovative Drug Development, Completed Pre-Series A Financing

On July 9, 2021, GenAssist has successfully closed a multi-million RMB Pre-Series A financing , bringing the total raised funds to nearly 100 million RMB. The round was led by Sequoia Capital China Fund, with participation from Westlake University Industrial Investment, Suzhou New District Industrial Investment, and the Wang Jiaquan Family Fund. Existing shareholder of

GenAssist, a Pioneer in the field of the Gene Editing Innovative Drug Development, Completed Pre-Series A Financing Read More »

GenAssist Completes Multi-Million Dollar Series A Financing

Recently, GenAssist, which is the first company in China to develop gene therapy drugs using base editing technology, announced the closing of a multi-million dollar Series A financing. The round was led by AstraZeneca-CICC Healthcare Industry Fund, with participation from Baidu Ventures (BV), a well-known equity investment institution, and existing shareholder Sequoia China, who continued

GenAssist Completes Multi-Million Dollar Series A Financing Read More »

Pre-IND application of GenAssist’s First DMD Drug was Accepted by the US FDA!

Recently, Suzhou GenAssisit Therapeutics Co.,Ltd. (hereinafter referred to as “GenAssist”) announced that its first base editing product, GEN6050, has submitted a pre-investigational new drug (Pre-IND) application to the FDA and has been accepted. GEN6050 is an in vivo base editing drug targeting exon 50 skipping for the treatment of Duchenne Muscular Dystrophy (DMD). The drug

Pre-IND application of GenAssist’s First DMD Drug was Accepted by the US FDA! Read More »